Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Erlotinib Treatment Beyond Progression in EGFR Mutant or Patients Who Have Responded EGFR TKI in Stage IIIB/IV NSCLC

NCT02064491 is registered in ClinicalTrials.gov with Finnish Lung Cancer Group as lead sponsor.

NCT NCT02064491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02064491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Erlotinib Treatment Beyond Progression in EGFR Mutant or Patients Who Have Responded EGFR TKI in Stage IIIB/IV NSCLC
Lead sponsor
Finnish Lung Cancer Group
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2014
Completion date
May 31, 2017
Enrollment
18 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer